Referencias Bibliográficas

1. Ramírez PT, Frumovitz M, Pareja R, López A, Vieira M, Ribeiro M, Buda A, Yan X, Shuzhong Y, Chetty N, et al. Minimally In-vasive versus Abdominal Radical Hysterectomy for Cervical Cancer. N Engl J Med. 2018;379:1895-904. doi: 10.1056/NEJ-Moa1806395 [ Links ]

2. Plante M, Kwon JS, Ferguson S, Samouëlian V, Ferron G, Mau-lard A, de Kroon C, Van Driel W, Tidy J, Williamson K, et al. Simple versus Radical Hysterectomy in Women with Low-Risk Cervical Cancer. N Engl J Med. 2024;390:819-29. doi: 10.1056/NEJMoa2308900 [ Links ]

3. Colombo N, Dubot C, Lorusso D, Cáceres MV, Hasegawa K, Shapira-Frommer R, Tewari KS, Salman P, Hoyos Usta E, Yañez E, et al. Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer. N Engl J Med. 2021;385:1856-67. doi: 10.1056/NEJMoa2112435 [ Links ]

4. Parisi S, Sciacca M, Ferrantelli G, Chillari F, Critelli P, Venuti V, Lillo S, Arcieri M, Martinelli C, Pontoriero A, et al. Locally advanced squamous cervical carcinoma (M0): management and emerging therapeutic options in the precision radiotherapy era. Jpn J Radiol. 2023;42:354-66. doi: 10.1007/s11604-023-01510-2 [ Links ]

5. Cibula D, Raspollini MR, Planchamp F, Centeno C, Chargari C, Felix A, Fischerová D, Jahnn-Kuch D, Joly F, Kohler C, Lax S, Lo-russo D, Mahantshetty U, Mathevet P, Naik R, Nout RA, Oaknin A, Peccatori F, Persson J, et al. ESGO/ESTRO/ESPGuidelinesfor the management of patients with cervical cancer - Update 2023 Int J Gynecol Cancer. 2023;33(5):649-66. doi: 10.1136/ijgc-2023-004429 [ Links ]

6. Olawaiye AB, Baker TP, Washington MK, Mutch DG. LThe new (Version 9) American Joint Committee on Cancer tumor, node, metastasis staging for cervical cancer. CA Cancer J Clin. 2021;71:287-98. doi: 10.3322/caac.21663 [ Links ]

7. Salib MY, Russell JHB, Stewart VR, Sudderuddin SA, Barwick TD, Rockall AG, Bharwani N. 2018 FIGO Staging Classification for Cervical Cancer: Added Benefits of Imaging. RadioGraphics. 2020; 40:1807-22. doi: 10.1148/rg.2020200013 [ Links ]

8. Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Can-cer of the cervix uteri: 2021 update. Int J Gynaecol Obstet. 2021;155(S1):28-44. doi: 10.1002/ijgo.13865 [ Links ]

9. Piver MS, Rutledge F, Smith JP. Five classes of extended hys-terectomy for women with cervical cancer. Obstet Gynecol. 1974;44:265-72. [ Links ]

10. Querleu D, Cibula D, Abu-Rustum NR. 2017 Update on the Quer-leu-Morrow Classification of Radical Hysterectomy. Ann Surg Oncol. 2017;24(11):3406-12. doi: 10.1245/s10434-017-6031-z [ Links ]

11. Querleu D, Morrow CP. Classification of radical hysterectomy. Lancet Oncol. 2008;9:297-300. [ Links ]

12. Lee SW, Kim Y-M, Son W-S, You H-J, Kim D-Y, Kim J-H, et al. The efficacy of conservative management after conization in patients with stage IA1 microinvasive cervical carcinoma. Acta Obstet Gynecol Scand. 2009;88:209-15. doi: 10.1080/00016340802596009 [ Links ]

13. Benedet JL, Anderson GH. Stage IA carcinoma of the cervix revisited. Obstet Gynecol. 1996;87:1052-9. doi: 10.1016/0029-7844(96)00051-8 [ Links ]

14. Elliott P, Coppleson M, Russell P, Liouros P, Carter J, MacLeod C, Jones M. Early invasive (FIGO stage IA) carcinoma of the cervix: a clinico-pathologic study of 476 cases. Int J Gynecol Cancer. 2000;10:42-52. doi: 10.1046/j.1525-1438.2000.00011.x [ Links ]

15. Diaz ES, Aoyama C, Baquing MA, Beavis A, Silva E, Holschneider C, Cass I. Predictors of residual carcinoma or carcinoma-in-situ at hysterectomy following cervical conization with positive margins. Gynecol Oncol. 2014;132:76-80. doi: 10.1016/j.ygy-no.2013.11.019 [ Links ]

16. Van Meurs H, Visser O, Buist M, Ten Kate F, Van der Belden J, et al. Frequency of pelvic lymph node metastases and parame-trial involvement in stage IA2 cervical cancer: a population-ba-sed study and literature review. Int J Gynecol Cancer. 2009 Jan;19(1):21-6. doi: 10.1111/IGC.0b013e318197f3ef [ Links ]

17. Costa S, Marra E, Martinelli GN, Santini D, Casadio P, Formelli G, et al. Outcome of conservatively treated microinvasive squamous cell carcinoma of the uterine cervix during a 10-year follow-up. Int J Gynecol Cancer. 2009;19:33-8. doi: 10.1111/IGC.0b013e318197f53b [ Links ]

18. Bouchard-Fortier G, Reade C, Covens A. Non-radical surgery for small early-stage cervical cancer. Is it time? Gynecol Oncol. 2014;132:624-7. doi: 10.1016/j.ygyno.2014.01.037 [ Links ]

19. Frumovitz M, Sun CC, Schmeler KM, Deavers MT, Dos Reis R, Levenback CF, Ramirez PT. Parametrial involvement in radical hysterectomy specimens for women with early-stage cervical cancer. Obstet Gynecol. 2009;114:93-9. doi: 10.1097/AOG.0b013e3181ab474d [ Links ]

20. Shepherd JH, Spencer C, Herod J, Ind TEJ. Radical vaginal tra-chelectomy as a fertility-sparing procedure in women with ear-ly-stage cervical cancer-cumulative pregnancy rate in a series of 123 women. BJOG. 2006;113(6):719-24. doi: 10.1111/j.1471-0528.2006.00936.x [ Links ]

21. Salvo G, Ramirez PT, Leitao MM, Cibula D, Wu X, Falconer H, et al. Open vs minimally invasive radical trachelectomy in early-stage cervical cancer: International Radical Trachelectomy Assessment Study. Am J Obstet Gynecol. 2022;226(1):97.e1-97. e16. doi: 10.1016/j.ajog.2021.08.029 [ Links ]

22. Chacon E, Manzour N, Zanagnolo V, Querleu D, Núñez-Cór-doba JM, Martin-Calvo N, et al. SUCCOR cone study: conization before radical hysterectomy. Int J Gynecol Cancer. 2022;32(2):117-24. doi: 10.1136/ijgc-2021-002544 [ Links ]

23. Abu-Rustum NR, Yashar CM, Arend R, Barber E, Bradley K, Brooks R, et al. NCCN Guidelines (r) Insights: Cervical Cancer, version 1.2024. J Natl Compr Cancer Netw. 2023;21:1224-33. doi: 10.6004/jnccn.2023.0062 [ Links ]

24. Marth C, Landoni F, Mahner S, McCormack M, Gonzalez-Martin A, Colombo N; ESMO Guidelines Committee. Cáncer de cuello uterino: pautas de práctica clínica de la ESMO para diagnóstico, tratamiento y seguimiento. Ann Oncol. 2017;28(4):iv72-iv83. doi: 10.1093/annonc/mdx120 [ Links ]

25. Landoni F, Maneo A, Cormio G, Perego P, Milani R, Caruso O, Mangioni C. Histerectomía radical de clase II versus clase III en cáncer de cuello uterino en estadio IB-IIA: un estudio prospectivo aleatorizado. Gynecol Oncol. 2001;80:3-12. doi: 10.1006/gyno.2000.5924 [ Links ]

26. Querleu D, Cibula D, Abu-Rustum N. 2017 Update on the Quer-leu-Morrow Classification of Radical Hysterectomy. Ann Surg Oncol. 2017 Oct;24(11):3406-12. doi: 10.1245/s10434-017-6031-z [ Links ]

27. Van Meurs H, Visser O, Buist MR, Ten Kate FJW, Van der Velden J. Frequency of pelvic lymph node metastases and parametrial involvement in stage IA2 cervical cancer: a population-based study and literature review. Int J Gynecol Cancer. 2009 Jan;19(1):21-6. doi: 10.1111/IGC.0b013e318197f3ef [ Links ]

28. Benedetti-Panici P, Maneschi F, Scambia G, Greggi S, Cutillo G, D'Andrea G, Rabitti C, Coronetta F, Capelli A, Mancuso S. Lymphatic spread of cervical cancer: An anatomical and pathological study based on 225 radical hysterectomies with systematic pelvic and aortic lymphadenectomy. Gynecol Oncol. 1996;62(1):19-24. doi: 10.1006/gyno.1996.0184 [ Links ]

29. Roh J-W, Lee DO, Suh DH, Lim MC, Seo SS, Chung J, et al. Effica-cy and oncologic safety of nerve-sparing radical hysterectomy for cervical cancer: A randomized controlled trial. J Gynecol Oncol. 2015;26:90-9. doi: 10.3802/jgo.2015.26.e36 [ Links ]

30. Abu-Rustum NR, Sonoda Y, Black D, Levine DA, Chi DS, Barakat RR. Fertility-sparing radical abdominal trachelectomy for cervi-cal carcinoma: Technique and review of the literature. Gynecol Oncol. 2006;103(3):807-13. doi: 10.1016/j.ygyno.2006.07.028 [ Links ]

31. Landoni F, Zanagnolo V, Lovato-Diaz L, Maneo A, Rossi R, Ga-dducci A, et al. Ovarian metastases in early-stage cervical cancer (IA2-IIA): A multicenter retrospective study of 1965 patients (a Cooperative Task Force study). Int J Gynecol Cancer. 2007;17:623-8. doi: 10.1111/j.1525-1438.2006.00870.x [ Links ]

32. Ramirez PT, Robledo KP, Frumovitz M, Pareja R, Ribeiro R, Lo-pez A, et al. LACC Trial: Final Analysis on Overall Survival Com-paring Open Versus Minimally Invasive Radical Hysterectomy for Early-Stage Cervical Cancer. J Clin Oncol. 2024;42(23):2741-6. doi: 10.1200/JCO.23.02335 [ Links ]

33. Falconer H, Palsdottir K, Stalberg K, Dahm-Kähler P, Ottander U, Serreyn Lundin E, et al. Robot-assisted approach to cervical cancer (RACC): An international multi-center, open-label ran-domized controlled trial. Int J Gynecol Cancer. 2019;29:1072-6. doi: 10.1136/ijgc-2019-000055 [ Links ]

34. Chao X, Li L, Wu M, Ma S, Tan X, Zhong S, et al. Efficacy of diffe-rent surgical approaches in the clinical and survival outcomes of patients with early-stage cervical cancer: Protocol of a phase III multicenter randomized controlled trial in China. BMJ Open. 2019;9:e029055. doi: 10.1136/bmjopen-2018-028416 [ Links ]

35. Lecuru F, Mathevet P, Querleu D, Leblanc E, Morice P, Daraï E, et al. Bilateral negative sentinel nodes accurately predict absence of lymph node metastasis in early cervical cancer: Results of the SENTICOL study. J Clin Oncol. 2011;29:1686-91. doi: 10.1200/JCO.2010.32.4735 [ Links ]

36. Rotman M, Sedlis A, Piedmonte MR, Bundy B, Lentz SS, Mu-derspach LI, et al. A phase III randomized trial of postoperative pelvic irradiation in cervical carcinoma stage IB with unfavora-ble prognostic features: Follow-up of a Gynecologic Oncology Group study. Int J Radiat Oncol Biol Phys. 2006; 65:169-76. doi: 10.1016/j.ijrobp.2005.05.033 [ Links ]

37. Sedlis A, Bundy BN, Rotman MZ, Lentz SS, Muderspach LI, Zai-no RJ, et al. A randomized trial of pelvic radiation therapy versus no further treatment in selected patients with stage IB cervical carcinoma following radical hysterectomy and pelvic lymphadenectomy: A Gynecologic Oncology Group study. Gynecol Oncol. 1999;73:177-83. doi: 10.1006/gyno.1998.5255 [ Links ]

38. Kenter G, Greggi S, Vergote I, Katsaros D, Kobierski J, Van Doorn H, et al. Neoadjuvant chemotherapy followed by surgery versus chemoradiation for stage IB2-IIb cervical can-cer: EORTC 55994. J Clin Oncol. 2019;37:5503. doi: 10.1200/JCO.2019.37.15_suppl.5503 [ Links ]

39. Gupta S, Maheshwari A, Parab P, Mahantshetty U, Hawaldar R, Chopra SS, et al. Neoadjuvant chemotherapy followed by radical surgery versus concurrent chemoradiation in patients with stage IB2, IIA, or IIB squamous cervical cancer: A ran-domized controlled trial. J Clin Oncol. 2018;36:1548-55. doi: 10.1200/JCO.2017.76.5437 [ Links ]

40. Dastidar GA, Gupta P, Basu B, Basu A, Shah JK, Seal SL. Is neoadjuvant chemotherapy a better option for the treatment of patients with cervical cancer in rural India? Indian J Cancer. 2016;53:56-9. doi: 10.4103/0019-509X.177876 [ Links ]

41. Ubinha ACF, Pedrão PG, Tadini AC, Schmidt RL, Dos Santos MH, Mattos da Cunha Andrade CE, et al. The role of pelvic exenteration in cervical cancer: A review of the literature. Can-cers. 2024;16(4):817. doi: 10.3390/cancers16040817 [ Links ]

42. Dutta S, Nguyen NP, Vock J, Kerr C, Godinez J, Bose S, et al. Ima-ge-guided radiotherapy and brachytherapy for cervical cancer. Front Oncol. 2015;5:64. doi: 10.3389/fonc.2015.00064 [ Links ]

43. Grigsby PW, Perez CA. Radiation therapy alone for medically inoperable cervical carcinoma: Stage IA and carcinoma in situ. Int J Radiat Oncol Biol Phys. 1991;21:375-8. doi: 10.1016/0360-3016(91)90061-D [ Links ]

44. Peters WA, Liu PY, Barrett 2nd RJ, Stock RJ, Monk BJ, Berek JS, et al. Concurrent chemoradiotherapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in early-stage, high-risk cervical cancer. J Clin Oncol. 2000;18:1606-13. doi: 10.1200/JCO.2000.18.8.1606 [ Links ]

45. Sedlis A, Bundy BN, Rotman MZ, Lentz SS, Muderspach LI, Zai-no RJ. A randomized trial of pelvic radiation therapy versus no further treatment in selected patients with stage IB cervical carcinoma following radical hysterectomy and pelvic lympha-denectomy: A Gynecologic Oncology Group study. Gynecol Oncol. 1999;73:177-83. doi: 10.1006/gyno.1998.5255 [ Links ]

46. Whitney CW, Sause W, Bundy BN, Malfetano JH, Hannigan EV, Fowler Jr WC, et al. Randomized comparison of fluoroura-cil plus cisplatin versus hydroxyurea as adjunct to radiation therapy in carcinoma of the cervix stage IIB-IVA with negative para-aortic nodes: A Gynecologic Oncology Group and Sou-thwest Oncology Group study. J Clin Oncol. 1999;17:1339-48. doi: 10.1200/JCO.1999.17.5.1339 [ Links ]

47. Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999;340:1137-43. doi: 10.1056/NEJM199904013401503 [ Links ]

48. Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA,et al. Concurrent cisplatin-based chemotherapy and radia-tion therapy for locally advanced cervical cancer. N Engl J Med. 1999;340:1144-53. doi: 10.1056/NEJM199904013401504 [ Links ]

49. Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs 3rd CL, Walker JL, Gersell D. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 1999;340:1154-61. doi: 10.1056/NEJM199904013401505 [ Links ]

50. Sardi JE, Boixadera MA, Sardi JJ. A critical view of concurrent chemoradiotherapy in cervical cancer. Curr Oncol Rep. 2004;6:463-70. doi: 10.1007/s11912-004-0007-1 [ Links ]